Comparative Pharmacology
Head-to-head clinical analysis: FLAXEDIL versus NIMBEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAXEDIL versus NIMBEX.
FLAXEDIL vs NIMBEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLAXEDIL (gallamine triethiodide) is a nondepolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at nicotinic receptors at the neuromuscular junction, preventing muscle contraction.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, blocking neurotransmission and inducing muscle relaxation.
0.08-0.12 mg/kg IV bolus for neuromuscular blockade; additional doses of 0.01-0.02 mg/kg as needed.
0.15-0.2 mg/kg IV bolus for intubation; maintenance infusion 1-2 mcg/kg/min (initial) adjusted to effect.
None Documented
None Documented
The terminal elimination half-life of gallamine is approximately 2-4 hours in patients with normal renal function. This half-life is inversely related to creatinine clearance, and may be prolonged to 12-24 hours or more in patients with renal impairment, leading to cumulative effects and prolonged neuromuscular blockade.
Terminal elimination half-life approximately 20-30 minutes in healthy adults; prolonged in hepatic or renal impairment.
Flaxedil (gallamine triethiodide) is excreted primarily unchanged by the kidneys via glomerular filtration. Approximately 90-95% of an administered dose is eliminated in urine within 24 hours, with the remainder excreted in feces (<5%) via biliary elimination.
Primarily renal (80% as unchanged drug and metabolites); biliary/fecal excretion accounts for <20%.
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent